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ABSTRACT The aim of this study was to analyze the characteristics and the treat-
ment for patients with psoriasis who presented with subsequent pemphigus after 
their treatment. A retrospective study of seven patients with psoriasis associated 
with pemphigus was performed, including the clinical assessment and treatments. 
The patients with a median age of 74 (range from 54 to 85) were significantly older 
than those in previously reported cases, where the median age was 58 (range from 
15 to 77) (P<0.05). Six out of seven patients were male, which represents a higher 
ratio than that reported in literature (10/20). The duration between the diagno-
sis of psoriasis and onset of pemphigus ranged from 4 to 30 years, and previous 
studies reported a much wider range that, from a few months to 52 years. Patients 
developed pemphigus after the treatments for psoriasis with ultraviolet light, ste-
roids, or immunosuppressant. Our study represents a distinct subset of patients 
with psoriasis accompanied with pemphigus who share typical clinical character-
istics. Among these patients, most are elderly men and the dominant subtype is 
pemphigus foliaceus. Our data suggests that no treatment for psoriasis specifically 
correlated with the development of pemphigus. The combination treatment of 
steroids with immunosuppressant lead to an improvement of the disease.
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INTRODUCTION
Psoriasis vulgaris is a well-characterized chronic 
inflammatory skin disorder which has recently been 
considered a systemic disease rather than an isolated 
dermatologic disorder with systemic inflammation 
(1) and a significantly increased risk of cardiovascu-
lar diseases (2,3). Cases of psoriasis associated with 
other common autoimmune diseases such as arthri-
tis, systemic lupus erythematosus (4), thyroiditis (5), 
multiple sclerosis, and inflammatory bowel disease 
(6) have been reported in previous studies. In 1978, 
Koerber et al. first reported some single instances 
of bullous disease associated with psoriasis (7). The 
most common types of autoimmune bullous dis-
eases consist of bullous pemphigoid and pemphigus, 
and several clinical studies have revealed that bullous 
pemphigoid was the major type associated with pso-
riasis (8-11). In contrast, there are only some sporadic 
case reports of pemphigus (pemphigus vulgaris and 
pemphigus foliaceus) that link to psoriasis vulgaris 
(12,13). To our knowledge, comprehensive analysis of 
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this “complication” of psoriasis is absent in the litera-
ture. Therefore, we investigated seven patients diag-
nosed with psoriasis and pemphigus to evaluate how 
pemphigus initiated and subsequently progressed 
in the context of psoriasis after their treatment, and 
we focused on their clinical features in particular. In 
addition, we reviewed and compared our findings 
in detail with the clinical case reports available in 
the medical literature. Furthermore, we will extend 




Seven patients from Rui Jin Hospital presenting 
with psoriasis followed by pemphigus were analyzed. 
Diagnosis was established based on clinical manifes-
tations, histopathology, immunofluorescence study, 
and enzyme-linked immunosorbent assay (ELISA) 
results of anti-Desmoglein 1 (Dsg1) and Desmoglein 
3 (Dsg3) antibodies. The retrospective study was 
conducted at Rui Jin Hospital from January 2001 to 
December 2016. Our study abided by the principles 
expressed in the Declaration of Helsinki and was ap-
proved by the Ethics and Scientific Committees of Rui 
Jin Hospital.
Observed factors
Sex, age, course of psoriasis, prior treatment for 
psoriasis, subtype of pemphigus, histopathology, di-
rect or indirect immunofluorescence results, titers of 
anti-Dsg autoantibodies by ELISA, and treatment for 
pemphigus of the seven patients were observed and 
summarized for analysis.
Literature review
Previous case reports of pemphigus associated 
with pre-existing psoriasis (20 individual cases) pub-
lished from 1985 to 2016 and retrieved from PubMed 
were reviewed. Sex, age, course of psoriasis, prior 
treatment for psoriasis, subtype of pemphigus, and 
treatment for pemphigus of the cases reported in 
literature were summarized and compared with our 
cases.
Statistical analysis
SPSS14.0 statistical software (SPSS. Inc. Chicago, 
IL, USA) was used for data analysis. Mann-Whitney U 
test and Fisher’s exact test were performed for quan-
titative data and qualitative data, respectively. P≤0.05 
was considered statistically significant.
RESULTS
Clinical and laboratory characteristics of 
the patients
Seven patients were enrolled and were diagnosed 
with psoriasis and pemphigus in Rui Jin Hospital from 
2001 to 2016. All cases were confirmed as pemphigus 
by the combination of the results of histology, immu-
nofluorescence (direct immunofluorescence and/or 
indirect immunofluorescence) study, and serologic 
test of anti-Desmoglein 1/Desmoglein 3 antibodies 
by ELISA. The clinical and immuno-histopathologic 
features of a representative patient with psoriasis 
and pemphigus are shown in Figure 1. The scattered 
papules with scale and superficial erosion with a 
positive Nikolsky’s sign were developed on his back. 
We performed a biopsy from each lesion, which were 
individually confirmed to be psoriatic and pemphi-
gus lesion. Direct and indirect immunofluorescence 
showed that immunoglobulin G (IgG) was deposited 
between the keratinocytes.
Summary of the observations
Our patients had a median age of 74 (range from 
54 to 85) (Table 1). The majority of them (6/7) were 
men (85.7%). The median duration of psoriasis was 10 
years (range from 4 to 30). Three of the seven patients 
had pemphigus vulgaris (pemphigus vulgaris, 42.9%) 
and four presented with pemphigus foliaceus (pem-
phigus foliaceus, 57.1%). Two patients had a history 
of ultraviolet B irradiation (28.6%) and five patients 
had a prior history of glucocorticoid treatments be-
fore pemphigus developed (71.4%). Low-dose of glu-
cocorticoids with immunosuppressive agents were 
efficient for treating their pemphigus. All of the seven 
patients with psoriasis vulgaris associated with pem-
phigus were treated with small doses of systemic glu-
cocorticoid combined with an immunosuppressive 
agent, such as azathioprine or methotrexate. The ma-
jority of the symptoms were relieved within 2 weeks. 
With clinical improvement, the dose of glucocorti-
coid was slowly tapered to 5 mg/day and the immu-
nosuppressive agent stopped. The disease condition 
of most of the patients improved during the taper-
ing of the oral steroid. Only one patient’s symptoms 
of psoriasis vulgaris worsened during the course 
of treatment, and the lesions were eventually con-
trolled by the additional application of topical steroid 
ointment.
Literature review
We studied 20 individual previous case reports 
of patients with psoriasis and pemphigus (Table 2) 
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(12-29). The patients had a median age of 58 (range 
from 15 to 77) which was significantly younger than 
that observed in our patients (P<0.05). Ten cases 
were women (10/20, 50.0%) and ten cases were men 
(10/20, 50.0%), which showed no statistical difference 
from that of our patients (P>0.05). All the patients pre-
sented with onset of pemphigus after the treatment 
for psoriasis within a variable duration ranging from 
several months to 52 years. Only one patient was 
reported to be diagnosed with psoriasis and pem-
phigus concurrently. Fifteen of these patients had 
pemphigus foliaceus (15/20, 75.0%) and five patients 
developed pemphigus vulgaris (5/20, 25.0%). Six pa-
tients had a history of using ultraviolet radiation (pso-
ralen ultraviolet A and ultraviolet B) (6/20, 30.0%) and 
four patients received glucocorticoid treatment for 
Figure 1. (a) The patient (the third patient in Table 1) presented with scattered papules on his lower back with scale; (b) 
The patient (the third patient in Table 1) had a typical pemphigus lesion on his back, which was characterized by superficial 
erosion and positive for Nikolsky sign; (c) The histopathologic features of the patient showed hyperparakeratosis, thinning 
and focal loss of the granular layer, and ectatic capillaries in the elongated dermal papillae which confirmed as psoriasis 
(hematoxylin and eosin (H&E), scale bar = 100 μm); (d) The histopathologic features of the patient showed acanthosis and 
partial separation of epidermis on one side of the sample with mild superficial lymphocytic perivascular infiltration that 
confirmed as pemphigus (H&E, scale bar = 100 μm); (e) Immunofluorescence of immunoglobulin G (IgG) deposited between 
keratinocytes via direct immunofluorescence assay (scale bar = 20 μm); (f ) Immunofluorescence of immunoglobulin G (IgG) 
deposited between keratinocytes via indirect immunofluorescence assay (scale bar = 20 μm).
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psoriasis (4/20, 20.0%). Three patients eventually de-
veloped pemphigus vulgaris after treatment with the 
immunosuppressant cyclosporine A (3/20, 15.0%).
Comparison of the cases
When combining data from the two tables (Table 
1, Table 2), we found that all these patients (n=27) 
had a combined median age of 62 years (range from 
15 to 85). About one-third of the patients were diag-
nosed with pemphigus vulgaris (8/27), while almost 
two-third of the patients developed pemphigus folia-
ceus (19/27) (Table 3).
DISCUSSION
Since the first report by Koerber et al. in 1978, 
case reports of bullous diseases that developed in 
patients with psoriasis have increased in number (7). 
This includes the predominant forms of bullous pem-
phigoid and the relatively rare forms of pemphigus, 
in which pemphigus foliaceus has been reported to 
be a more frequent disease than pemphigus vulgaris 
(8). Over the previous 20 cases, 15 of these patients 
presented with pemphigus foliaceus (15/20, 75.0%) 
and 5 patients developed pemphigus vulgaris (5/20, 
25.0%). In order to clarify pemphigus onset and sub-
sequent progression in the context of psoriasis after 
their treatment, we studied the clinical features of 
these patients with psoriasis vulgaris that following 
pemphigus after their treatment. Herein we reported 
seven cases of pemphigus arising in patients with 
psoriasis. Interestingly, in our seven cases, more than 
half of the patients also developed pemphigus folia-
ceus (4/7, 57.1%), which is consistent with what we 






























0.16 (Dsg1) Steroid ointment, 
tacrolimus ointment
2 Male/74 30 Steroid 
ointment, 
amlodipine
PF Complied with 
psoriasis

























N/A 66.60 (Dsg1) Prednisone, 
cyclosporine







N/A Tripterygium steroid 
ointment
6 Male/70 10 N/A PV Complied with 
pemphigus
N/A N/A Methylprednisolone  
azathioprine
7 Male/85 10 Steroid 
ointment








Note: DIF: Direct immunofluorescence, IIF: Indirect immunofluorescence, UVB: Ultraviolet B, PF: Pemphigus foliaceus, PV: 
Pemphigus vulgaris, ELISA: Enzyme linked immunosorbent assay, MTX: Methotrexate, Dsg: Desmoglein, N/A: Information not 
available.
Table 1. Summary of seven psoriasis patients associated with pemphigus.
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A number of potential mechanisms have been 
proposed to account for this association. Several ther-
apeutic options for psoriasis have been considered 
as independent triggers of pemphigus, including 
phototherapy (psoralen ultraviolet A and ultraviolet 
B), medication such as etanercept and enalapril, and 
topical medications such as dithranol and salicylic 
acid (14,25). However, removal of these treatments 
has rarely resulted in the relief of the bullous diseases. 
We also found that ten patients in total (10/27) had 
a history of ultraviolet irradiation before pemphigus, 
suggesting that ultraviolet irradiation may play a role 
in pemphigus pathogenesis. Interestingly, we found 
that three patients who later developed pemphigus 
vulgaris had used cyclosporine A as the treatment for 
psoriasis (Table 2). Therefore, we predicted that cyclo-
sporine A might have an effect on cell-cell adhesion 
























Yokoo et al. 1989 Male/51 8 months Topical treatments PF Prednisolone
Lee and Ro 1994 Female/40 10 years Topical treatments PF Methotrexate
Fryer and Lebwohl 1994 Female/45 9 years PUVA PV N/A
Perez et al. 1995 Male/38 N/A Topical treatments PF Methotrexate
Aghassi and Dover 1998 Male/45 N/A PUVA PF Prednisolone
Tomasini et al. 1998 Male/72 52 years Topical treatment PF Prednisolone




















Gurgen and Dorton 2010 Male/70 N/A Betasol propionate PV
Prednisone, 
mycophenolate mofetil




Kwon et al. 2011 Male/53 13 years Topical steroids UVB PF
Prednisolone, 
azathioprine
Rallis et al. 2011 Female/71 3 years Cyclosporine PV Cyclosporine
















Kurtzman DJ et al. 2015 Female/62 Several months UVB PF
Systemic corticosteroids, 
azathioprine.
Claus S et al. 2016 Female/63 Decades N/A PF
Systemic corticosteroids, 
azathioprine
Note: UVB: Ultraviolet B, PUVA: Psoralen ultraviolet A, PF: Pemphigus foliaceus, PV: Pemphigus vulgaris, N/A: Information 
not available.
Table 2. Reported cases of psoriasis associated with pemphigus.
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Additionally, pemphigus is regarded as an auto-
immune disease mediated by pathogenic but not 
nonpathogenic autoantibodies against Desmoglein 
3 and/or Desmoglein 1 in the serum of patients. As 
the association of pemphigus with many other im-
mune disorders has been frequently reported (6), it is 
also believed that the hyperactivated immunologic/
inflammatory status found in patients with psoriasis 
may cause the loss of the T- and B-cell self-tolerance 
to the pemphigus antigens, Desmoglein 1 and Des-
moglein 3, and the presence of hypersensitive genet-
ic factors may lead to the production of the autoanti-
bodies and blister formation in pemphigus (30). 
Another possible mechanism of the association is 
genetic predisposition. Several clinical studies have 
shown that patients with pemphigus had genetic 
susceptibility to pemphigus vulgaris. Several human 
leukocyte antigen class II alleles (such as DRB1*04, 
DRB1*08, and DRB1*14) have been reported to be 
related to pemphigus (31,32). Recently, in the hu-
manized human leukocyte antigen-DRB1*04:02-
transgenic mouse model, the human leukocyte an-
tigen-DRB1*04:02-restricted CD4+ T-cells that are 
specifically reactive to human Desmoglein 3 epitopes 
were shown to help B-cells produce pathogenic pem-
phigus immunoglobulin G antibodies, indicating that 
genetic predisposition could be a major triggering 
factor for pemphigus in psoriasis (33). However, we 
would require further studies to confirm whether our 
patients with psoriasis have these associated human 
leukocyte antigen alleles.
On the other hand, the onset of pemphigus in 
psoriasis could also only be a coincidence. When 
combining our data with those from the literature, 
we found that the combined median age of 62 years 
(range from 15 to 85) was similar to the age of the 
overall pemphigus population (34). Interestingly, we 
also found that the ratio of the patients with pem-
phigus vulgaris and with pemphigus foliaceus was 
around 1:2 (8/27 vs. 19/27), which was not consistent 
with that of the overall distribution of pemphigus.
CONCLUSION
In addition to this analysis and comparison, we 
shared our clinical experience of the treatment for 
the co-existing diseases. We treated our patients with 
psoriasis associated with pemphigus with a combina-
tion of steroids and immunosuppressant, which re-
sulted in a dramatic reduction of the psoriatic lesions. 
Moreover, careful examination of the triggering fac-
tors in our patients could lead to a significant finding, 
apart from the fact that five out of our seven patients 
had a prior history of steroid application.
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